Lindahl advises Medivir on rights issue of approximately SEK 151 million

Medivir is a pharmaceutical company focused on developing innovative cancer treatments. The company's leading asset, fostroxacitabine bralpamide (fostrox), is being developed as an orally administered prodrug for hepatocellular carcinoma (HCC) – the most common form of liver cancer.

The rights issue was approved at an extraordinary general meeting on 10 November 2025 and the subscription period ran from 17 November to 2 December 2025. The issue was fully guaranteed through subscription and guarantee commitments from existing and new shareholders as well as from members of Medivir's board and management.

The net proceeds from the rights issue are primarily used to finance a randomised, controlled two-arm study with 30–50 patients in each arm, for repayment of a loan agreement with Linc AB and for general corporate purposes and extension of the company's cash resources until the end of 2027.

Lindahl's team consisted of Erika Svensson, Emelie Carmhagen, Theo Biström and Anna Drogou.

About our client Medivir

Medivir AB (publ) is a pharmaceutical company focused on developing innovative cancer treatments in areas of significant medical need. The company's leading asset, fostroxacitabine bralpamide (fostrox), is being developed as an orally administered prodrug for hepatocellular carcinoma (HCC) – the most common form of liver cancer and the fifth most common cancer globally. Fostrox has received orphan drug status from both the FDA and EMA. Medivir's share is listed on Nasdaq Stockholm's list for small companies (Small Cap).

Read more in Medivir's press release here.